Affymax, Inc. (Nasdaq: AFFY) today announced that it has instituted a quiet period to curtail discussions with the investor community and the media in connection with the analysis of Phase 3 results for the investigational drug, Hematide, in four clinical trials (PEARL 1, PEARL 2, EMERALD 1 and EMERALD 2) which evaluated Hematide for the treatment of anemia in chronic renal failure patients.
As analysis of data from the first of the four trials begins, the company expects that full data gathering and analysis will take a period of weeks before top line results are announced some time in June 2010. The company expects to lift the quiet period following disclosure of Phase 3 results.